Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Medtronic plc    MDT   IE00BTN1Y115


Real-time Estimate Quote. Real-time Estimate Cboe BZX - 01/21 11:05:00 am
117.565 USD   -1.45%
01/20Quarterly Report I 20/21
01/19Zimmer Biomet Appoints Chief Transformation Officer
01/15MEDTRONIC : NANS 2021 Neuromodulation Investor Briefing
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Medtronic : Receives Health Canada Licence for the First-of-Its-Kind Percept™ PC Neurostimulator with Brainsense™ Technology

10/29/2020 | 02:12pm EST

Next-Generation Technology Makes Percept™ the First and Only DBS System with Ability to Capture Patient-Specific Brain Signals for More Personalized, Data-Driven Treatment

BRAMPTON, ON, Oct. 29, 2020 /CNW/ - Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) – the world's largest medical technology, services, and solutions companies – announced today that it has received a Health Canada licence for the Percept™ PC Deep Brain Stimulation (DBS) system with BrainSense™ Technology. BrainSense technology makes Percept the first and only licensed DBS neurostimulation system with the ability to chronically capture and record brain signals while delivering therapy to patients with neurologic disorders associated with Parkinson's disease, essential tremor, dystonia, or epilepsy. Physicians can now track patient brain signals and correlate these with patient-recorded actions or experiences, such as symptoms, side-effects, or medication intake. This enables more personalized, data-driven neurostimulation treatment. The first implant of the newly licensed device in Canada will occur at Toronto Western Hospital.

"Percept is the first commercially available implantable pulse generator with the ability to record and store the day-to-day brain activity of patients with implanted electrodes for deep brain stimulation," said Dr. Alfonso Fasano, M.D., Ph.D., neurologist and professor of neurology at the University of Toronto. "Neurologists will have, for the first time, the opportunity to monitor their patients' condition well beyond the relatively short time devoted to the doctor-patient interaction in the clinic. Percept will also expand our understanding of brain functioning during physiological and pathological states and set the stage for the development of closed-loop (i.e. adaptive) deep brain stimulation."

DBS is an individualized therapy delivered from a small pacemaker-like device, placed under the skin of the chest or abdomen, to send electrical signals through very thin wires (leads) to a targeted area in the brain related to the symptoms of a neurological disorder, such as Parkinson's disease.

In addition to BrainSense technology, the Percept PC DBS system features several leading-edge innovations, including:

  • The only DBS system eligible for 3T and 1.5T full-body MRI scans, providing patients access to cutting-edge medical imaging.
  • Smart battery for personalized prediction of remaining battery life providing elevated peace of mind while planning for device replacement.
  • Improved battery longevity compared to Medtronic's Activa™ PC neurostimulator (when using similar settings and functionality) in a smaller (reduced volume), ergonomic design for patient comfort.
  • Low pulse width (duration of the pulse), providing expanded stimulation options.
  • Enhanced Patient Programmer leveraging a user-friendly, custom-configured Samsung mobile device that helps patients manage their therapy more easily.
  • Designed to facilitate expanded capabilities in the future via software upgrades – to prepare for what's next in DBS.

"There is nothing currently available that can replace clinical judgement in treating patients. For the first time, this technology gives clinicians feedback directly from the DBS patient's brain," said Mike Daly, vice president and general manager of the Brain Modulation business, which is part of the Restorative Therapies Group at Medtronic. "With such data-driven, patient-specific insights, we believe it can change the standard of care."

For further information on the Percept PC Neurostimulator with BrainSense Technology, please visit: Medtronic.ca/Percept

About Medtronic DBS Therapy
DBS therapy is currently licensed in many locations around the world, including the United States, Europe and Canada, for the treatment Parkinson's disease, essential tremor, dystonia, and epilepsy.

DBS therapy uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver electrical stimulation to precisely targeted areas of the brain as adjunctive treatment for several neurological disorders. Medtronic was the first in Canada to offer full-body MR Conditional DBS systems for patients to have safe scans anywhere on the body under certain conditions. Since 1987, more than 175,000 Medtronic DBS devices have been implanted worldwide for movement disorders and other indications.

About Medtronic Canada
Proudly serving Canadian healthcare for over 50 years, Medtronic Canada ULC (www.medtronic.ca), is a subsidiary of Medtronic plc, the world's largest medical technology, services, and solutions companies – alleviating pain, restoring health, and extending life for millions of people around the world. Serving physicians, hospitals, and patients across the country, Medtronic Canada ULC is headquartered in Brampton, Ontario, with regional offices in Montreal and Vancouver, and a Medtronic Resource Centre in Surrey, BC. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

SOURCE Medtronic Canada ULC

© Canada Newswire, source Canada Newswire English

All news about MEDTRONIC PLC
01/20Quarterly Report I 20/21
01/19Zimmer Biomet Appoints Chief Transformation Officer
01/15MEDTRONIC : NANS 2021 Neuromodulation Investor Briefing
01/15MEDTRONIC : Launches First-of-Its-Kind Adaptive Deep Brain Stimulation Trial in ..
01/14MEDTRONIC : Starts Adaptive Deep Brain Stimulation Trial in Parkinson's Disease ..
01/14MEDTRONIC : Launches First-of-Its-Kind Adaptive Deep Brain Stimulation (aDBS) Tr..
01/13Intel Ousts Chief Executive Bob Swan -- 5th Update
01/13Intel Ousts Chief Executive Bob Swan -- 4th Update
01/13BRIAN KRZANICH : Intel taps VMware's Gelsinger as CEO to fix manufacturing crisi..
01/13Intel Ousts Chief Executive Bob Swan -- 3rd Update
More news
Financials (USD)
Sales 2021 29 960 M - -
Net income 2021 3 484 M - -
Net Debt 2021 20 868 M - -
P/E ratio 2021 46,0x
Yield 2021 1,89%
Capitalization 161 B 161 B -
EV / Sales 2021 6,06x
EV / Sales 2022 5,49x
Nbr of Employees 90 000
Free-Float 99,9%
Duration : Period :
Medtronic plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Average target price 128,88 $
Last Close Price 119,29 $
Spread / Highest target 25,7%
Spread / Average Target 8,04%
Spread / Lowest Target -3,60%
EPS Revisions
Managers and Directors
Geoffrey Straub Martha Chairman & Chief Executive Officer
Mark Ploof Senior VP-Global Operations & Business Services
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Richard E. Kuntz Senior VP, Chief Scientific & Clinical Officer
Richard H. Anderson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC1.84%160 567